Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (\< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic resistance profile in case of virological failure CD4 changes from baseline Evolution of the lipid profile and morphological changes in fat distribution, and safety Efficacy and genotypic profile data, results of lipid markers, morphological changes and main biological parameters
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
140
France and French West Indies
Paris, France
Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48)
Time frame: 48 wks
Comparison of the two arms for genotypic resistance profile in case of virological failure
Time frame: 48 wks
CD4 changes from baseline
Time frame: 48 wks
Evolution of the lipid profile and morphological changes in fat distribution, and safety
Time frame: 48 wks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.